Covıd-19, Coronavirus, Drug, India

Covıd-19, Coronavirus

Sun Pharma latest to sell COVID-19 drug favipiravir in India

Sun Pharma latest to sell COVID-19 drug favipiravir in India

4/8/2020 1:58:00 PM

Sun Pharma latest to sell COVID-19 drug favipiravir in India

India 's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic ...

BookmarkBENGALURU: India's Sun Pharmaceutical Industries Ltd said on Tuesday (Aug 4) it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.

Victoria JC student infected with Covid-19; 103 people quarantined, 2,200 others to be swabbed 7 community cases among 20 new COVID-19 infections in Singapore Victoria Junior College student positive for COVID-19; more than 100 students, staff members quarantined

Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday.AdvertisementAdvertisement

Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees ($0.47) per 200 mg tablet, making it the cheapest version available. Stocks will be available from this week.Shares in Sun Pharma, one of the world's largest generic drug manufacturers, climbed after the news and were last up 1.7 per cent in an upbeat Mumbai market.

Favipiravir was originally developed by Japan's Fujifilm Holdings Corp as Avigan. Once hyped as a potential COVID-19 treatment by Japan's prime minister, Avigan faces uncertain prospects in the country, dampened by disappointing clinical studies.

Still, Indian regulators gave emergency approval to favipiravir in June in an effort to tackle the"urgent and unmet" need for COVID-19 treatments in the country.AdvertisementAdvertisementSeparately, another Indian drugmaker, Jubilant Life Sciences Ltd, on Monday announced the launch of its version of remdesivir, priced at 4,700 rupees per 100 mg vial. Jubilant is among the companies producing the drug under licence from US-based Gilead Sciences Inc.

Read more: CNA »

S'pore-HK air travel bubble starts May 26, 2 daily flights capped at 200 passengers each for first 2 weeks

Hyphens Pharma expands brand portfolio with hair-loss productsHYPHENS Pharma on Monday said that it has procured all rights, titles and interests in the trademarks of hair-loss products CG 210 and CG4S from Legacy Healthcare (Switzerland) for Singapore and Malaysia, paving the way for it to sell and distribute the CG 210 product series and the CG4S shampoo in the two countries. Read more at The Business Times.

Pharma giant Sanofi charged with manslaughter in birth defects casePARIS (AFP) - French prosecutors have indicted pharma giant Sanofi for manslaughter over birth defects linked to an epilepsy drug, the company said on Monday (Aug 3), in a long-running case that has also seen it charged with fraud.. Read more at

TikTok owners will relocate to London from Beijing, Sun newspaper saysByteDance’s founders are to announce their intention to set up shop in London soon, the newspaper said, adding that the move was likely to upset U.S.

India's Wockhardt to supply millions of doses of Covid-19 vaccines to UKBENGALURU (REUTERS) - India n drugmaker Wockhardt Ltd will supply millions of doses of multiple CoviD-19 vaccines to the UK, including the one being developed by AstraZeneca and Oxford University, it said on Monday (Aug 3).. Read more at

India's interior minister hospitalised with COVID-19 India 's Interior Minister Amit Shah said on Sunday that he had tested positive for coronavirus and had been admitted to hospital.

Eli Lilly tests antibody drug to halt COVID-19 spread in US nursing homesINDIANAPOLIS: Eli Lilly and Co said on Monday (Aug 3) it started a late-stage trial testing whether one of its experimental COVID-19 antibody ...